About

Michael A. Sherman has served on Aktis Oncology's board of directors since August 2025. He previously served as Chief Executive Officer of Chimerix and, before that, as President and Chief Executive Officer of Endocyte until its acquisition by Novartis in 2018, having joined Endocyte as Chief Financial Officer and Chief Operating Officer. He currently serves on the board of Werewolf Therapeutics and holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth.

Roles

Aktis Oncology, Inc.
Director · Current role
August 2025–present
Chimerix, Inc.
Chief Executive Officer (later Board Chair) · Board chair August 2023 - April 2025
April 2019 - July 2023
Endocyte, Inc.
President and Chief Executive Officer · Acquired by Novartis; joined 2006 as CFO and COO
June 2016 - December 2018

External Roles

Werewolf Therapeutics, Inc.
Director
May 2021 - present

Also at Aktis Oncology, Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.